haematology

News in brief: NVAF patients on DOACs at lower stroke/SE risk versus warfarin; Systemic cancer therapy not affected by pandemic; Doctor wins $450 damages for malicious reviews

NVAF patients on DOACs at lower stroke/SE risk versus warfarin Non-valvular atrial fibrillation (NAVF) patients with high risk of gastrointestinal (GI) bleed appear less likely to suffer stroke or systemic embolism (SE) while on non-vitamin K antagonist oral anticoagulants (DOACs) than warfarin, a study suggests. Published in JAMA Network Open, the study compared stroke and/or ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic